Triple therapy, transplantation and maintenance until progression to myeloma

From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (PGR, MF, MKS, KM, MEM, AAZ, ON, RLS, JPL, CP-P., IMG, KCA, NCM). Department of Data Science, Dana-Farber Cancer Institute (SJJ, KH), Department of Hematology and Oncology, Boston Children’s Hospital (EAW), Center for Multiple Myeloma, Massachusetts General Hospital (NSR, AJY), Harvard Medical School (PGR), SJJ, EAW, NSR, AJY. MF, KH, MKS, KM, MEM, AAZ, ON, RLS, JPL, CP-P., IMG, KCA, NCM), and Veterans Affairs Boston Healthcare System (NCM), Boston, and Department of Medical Oncology, Davenport-Mugger Cancer Center, Cape Cod Hospital, Hyannis (THO) – all in Massachusetts; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hussoun, SAG), and Department of Hematology and Medical Oncology, Mount Sinai (SJ), New York, Department of Medicine, Icahn School of Medicine Park Comprehensive Cancer Center in Roswell, Buffalo ( PLM, PT), and the State University of New York Upstate Medical University, Syracuse (TG) – all in New York; Winship Cancer Institute of Emory University, Atlanta (SL, JLK); Knight Cancer Institute, Oregon Health and Science University, Portland (EM, ES); Department of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (ENL); Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (PMV), Duke University Medical Center, Durham (CG), and Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (DDH) ) — all in North Carolina; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center (RZO), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (RTK), Houston, and the Myeloma, Waldenstrom, and Amyloidosis Program, Simmons Comprehensive Cancer Center , University of Texas Southwestern Medical Center, Dallas (LDA) – all in Texas; Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (JAZ), and Department of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (ELC) – both in Michigan; Department of Hematology and Oncology, University of Mississippi Medical Center, Jackson (CPM); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (MEA), and Abramson Cancer Center, University of Pennsylvania, Philadelphia (ADC) – both in Pennsylvania; Department of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus (AMK); Department of Bone Marrow Transplantation and Cellular Therapy, University of Arizona, Tucson (KG); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (NN), and Department of Medicine, Department of Hematology, Stanford University, Stanford (ML) – both in California; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (RFC); Department of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (ACA), and Cancer Care Center of Maine, Bangor (THO); O’Neill Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham (KNG); International Center for Blood and Marrow Transplantation Research (CIBMTR), Department of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (MCP); National Marrow Donor Program, CIBMTR, Minneapolis (AF); and the Department of Hematology (AP, M. Atal) and the Unit for Genomics in Myeloma (HA-L.), Institut Universitaire du Cancer de Toulouse-Oncopol, University Hospital, Toulouse, and Department of Hematology, University Hospital Htel-Dieu, Nantes ( PM) – both in France.

Dr. Richardson can be contacted OR at the Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Dana 1B02, Boston, MA 02115.

Author: Admin

Leave a Reply

Your email address will not be published.